Drugs /

pramlintide

Back to Drugs List

Overview

NCI Definition [1]:
A peptide analogue of human amylin with 3 proline substitutions at positions 25, 28 and 29, with antihyperglycemic activity. By mimicking amylin, pramlintide slows gastric emptying, inhibits digestive secretions (gastric acid, pancreatic enzymes, and bile), reduces glucagon secretion, and increases satiety; all of these actions are mediated mostly by glucose-sensitive areas in the brain stem. The overall result is a decrease in blood glucose levels. The use of pramlintide may cause an increased risk of insulin-induced hypoglycemia.

Clinical Trials

View Clinical Trials for pramlintide

Pramlintide has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating pramlintide, 1 is early phase 1 (1 open).

Skin squamous cell carcinoma is the most common disease being investigated in pramlintide clinical trials [2].

Drug Details

Synonyms [2]:
pramlintide (substance), pramlintide (product), triproamylin, pramlintide, pramlintide [chemical/ingredient], pramlintide
NCIT ID [1]:
C61901
SNOMED ID [1]:
F-61F9D

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.